KGOG-1024模型预测宫颈癌同步放化疗后远处复发风险的验证研究
本研究在297例接受同步放化疗的局部晚期宫颈癌患者中回顾性验证KGOG-1024风险模型预测远处失败风险的表现,将患者分为低、中、高危三组,比较计算风险与实际观察风险。结果显示模型整体预测较准确,低危和中危组吻合较好,高危组计算风险高于实际观察。
要点
- KGOG-1024模型将患者分为低危27.2%、中危49.3%、高危23.5%。
- 低危组5年累积发生率计算值12.4% vs 观察值16.4%。
- 中危组23.2% vs 25.9%,高危组50.7% vs 36.3%,整体26.7% vs 25.6%。
核心结论
- KGOG-1024风险模型能较准确预测局部晚期宫颈癌同步放化疗后远处复发,尤其在低危和中危组。
研究设计与样本
- 回顾性队列研究,纳入297例接受同步放化疗的晚期宫颈癌患者,使用KGOG-1024模型计算个体风险并分为三组。
主要发现
- 低危组5年累积远处复发率计算值12.4% vs 观察值16.4%。
- 中危组计算值23.2% vs 观察值25.9%。
- 高危组计算值50.7% vs 观察值36.3%。
- 整体计算风险26.7% vs 观察风险25.6%。
关键数值与推荐
- 按KGOG-1024模型风险分为低危(27.2%)、中危(49.3%)、高危(23.5%)。
临床怎么用
- 该模型可用于识别同步放化疗后可能从辅助全身治疗试验中获益的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study aimed to validate the performance of the Korean Gynecologic Oncologic Group (KGOG)-1024 risk model in predicting the risk of distant failure after chemoradiation in patients with locally advanced cervical cancer (LACC). METHODS: In a retrospective cohort of 297 patients who received concurrent chemoradiation for advanced cervical cancer, individual risk was calculated using the KGOG-1024 risk model. The cohort was categorized into three risk groups (low-, intermediate-, and high-risk groups) according to the calculated risk. The means of the calculated and observed risks were compared within each group. RESULTS: The study population was classified into low-, intermediate-, and high-risk groups according to the KGOG-1024 risk model (27.2%, 49.3%, and 23.5% of patients, respectively). The calculated and observed 5-year cumulative incidence rates were 12.4% vs. 16.4% in the low-risk group, 23.2% vs. 25.9% in the intermediate-risk group, and 50.7% vs. 36.3% in the high-risk group. Overall, the calculated and observed risk was 26.7% vs. 25.6%. CONCLUSIONS: The KGOG-1024 risk assessment model accurately predicted distant recurrence after chemoradiation in patients with LACC, especially in the low- and intermediate-risk groups. The model may be helpful for identifying patients for future trials assessing the possible benefit of adjuvant systemic treatment after chemoradiation.
引用
- Shin W, Park SY, Seo SS, et al. Predicting the risk of the distant recurrence of cervical cancer after concurrent chemoradiation: A validation study of the Korean Gynecologic Oncologic Group (KGOG)-1024 model. Gynecol Oncol. 2021. PMID: 34696893. doi:10.1016/j.ygyno.2021.10.070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。